A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3)

  • End date
    Dec 14, 2024
  • participants needed
  • sponsor
    Erasca, Inc.
Updated on 14 June 2022


  • To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies.
    • To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other cancer therapies.
    • To evaluate the antitumor activity of ERAS-007 in combination with other cancer therapies.
    • To evaluate the PK profiles of ERAS-007 and other cancer therapies when administered in combination.


This is a Phase 1b/2, open-label, multicenter clinical study evaluating ERAS-007 in combination with other cancer therapies in study participants with GI malignancies. This study will serve as a platform study, allowing for evaluation of safety/tolerability and efficacy of ERAS-007 in combination with other cancer therapies. The study will initially commence with dose escalation of ERAS-007 administered in combination with encorafenib and cetuximab in study participants with metastatic colorectal cancer (CRC) harboring B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E mutation; and dose escalation of ERAS-007 administered in combination with palbociclib in study participants with metastatic CRC harboring Kirsten rat sarcoma (KRAS) or neuroblastoma rat sarcoma (NRAS) mutations. Dose expansion will follow and will test ERAS-007 administered at the RD identified from each dose escalation arm in study participants with metastatic CRC.

Condition Metastatic Colorectal Cancer
Treatment Cetuximab, Palbociclib, Encorafenib, ERAS-007
Clinical Study IdentifierNCT05039177
SponsorErasca, Inc.
Last Modified on14 June 2022


Yes No Not Sure

Inclusion Criteria

Age ≥ 18 years
Willing and able to give written informed consent
Have histologically or cytologically confirmed metastatic CRC harboring applicable mutation(s) (e.g., BRAF V600E; KRAS or NRAS mutations) based on an analytically validated assay performed on tumor tissue in a certified testing laboratory
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Adequate bone marrow and organ function
Have ECOG performance status of 0 or 1
Willing to comply with all protocol-required visits, assessments, and procedures
Able to swallow oral medication

Exclusion Criteria

Prior therapy with a RAS, MEK, or ERK inhibitor. Depending on which treatment arm the patient is assigned, other therapies could also be prohibitive
Anti-cancer therapy ≤ 21 days or 4 half-lives prior to first dose of study drug, whichever is shorter
Palliative radiation ≤ 7 days prior to first dose of study drug
Symptomatic brain metastasis or leptomeningeal disease
Gastrointestinal conditions that may affect absorption of oral medications
Active infection requiring systemic therapy, or history of HIV infection, hepatitis B virus, or hepatitis C virus
History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ≤ 12 months prior to first study drug dose
Active, clinically significant interstitial lung disease or pneumonitis
Impaired cardiovascular function or clinically significant cardiovascular disease
History of thromboembolic or cerebrovascular events ≤ 6 months prior to first dose
Major surgery within 28 days of enrollment, or anticipation of major surgery during study treatment
Known intolerance or contraindication to encorafenib, cetuximab, or palbociclib
Pregnant or breastfeeding women
Any evidence of severe or uncontrolled systemic disease or evidence of any other significant clinical disorder or laboratory finding that renders the patient inappropriate to participate in the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note